<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>25098218</identifier>
<setSpec>0016-3813</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Lara Padilla, Eleazar</dc:author>
<dc:author>López Alvarenga, Juan Carlos</dc:author>
<dc:author>Gutiérrez Iglesias, Gisela</dc:author>
<dc:author>Amancio Chasin, Octavio</dc:author>
<dc:author>Hernández Ruiz, Joselín</dc:author>
<dc:author>García García, José Antonio</dc:author>
<dc:author>Alvarez Hernández, Everardo</dc:author>
<dc:author>Sánchez Pedraza, Valentín</dc:author>
<dc:author>Ocharán Hernández, María Esther</dc:author>
<dc:author>Melendro Lozano, Emma Isabel</dc:author>
<dc:description xml:lang="en">INTRODUCTION Obesity is associated with low-intensity chronic systemic inflammation. OBJECTIVE To evaluate the efficacy of two different doses of metformin in comparison with placebo on increased serum levels of high molecular weight (HMW) adiponectin. MATERIAL AND METHODS An experimental design was developed with a crossover complete treatment and balanced design; 28 female and eight male nondiabetic obese adults participated. All participants received, during a week and in randomized order: placebo or metformin 500 or 850 mg twice daily; there was a week washout period between each treatment. The HMW adiponectin serum concentration (0 and 120 minutes) at the end of each treatment was measured. Analyses of variance (ANOVA), Bonferroni test, and size effect calculations were performed. RESULTS Differences in concentrations of HMW adiponectin (t0', t120') were measured for each treatment by ANOVA, having values of p = 0.03 and 0.002, respectively. The post hoc analysis reported differences favoring treatment with metformin 850 mg (p = 0.025). The sizes of the effect at times t0 and t120 for metformin 500 mg were 34 and 35%, and for metformin 850 mg, 65 and 84%, respectively.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2014 Jul-Aug </dc:date>
<dc:title xml:lang="es">La metformina incrementa la concentración sérica de adiponectina de alto peso molecular (adiponectina-HMW) en obesos no diabéticos.</dc:title>
<dc:title xml:lang="en">[Metformin increases serum concentration of high molecular weight (HMW-adiponectin) in nondiabetic obese subjects].</dc:title>
<dc:publisher>Gaceta medica de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
